Concert Pharmaceuticals (CNCE) Earning Somewhat Favorable Media Coverage, Analysis Shows

News stories about Concert Pharmaceuticals (NASDAQ:CNCE) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.8272996766584 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

NASDAQ CNCE traded up $0.37 during trading on Tuesday, hitting $20.20. The stock had a trading volume of 145,988 shares, compared to its average volume of 395,426. The stock has a market capitalization of $460.95, a price-to-earnings ratio of 4.95 and a beta of 1.01. Concert Pharmaceuticals has a 12 month low of $11.88 and a 12 month high of $30.71.

How to Become a New Pot Stock Millionaire

Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.08). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $8.11 million. Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. sell-side analysts forecast that Concert Pharmaceuticals will post -2.35 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on CNCE shares. BidaskClub cut Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Mizuho reiterated a “hold” rating and set a $23.00 price objective on shares of Concert Pharmaceuticals in a report on Tuesday, February 13th. UBS set a $34.00 price objective on Concert Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 19th. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price objective on shares of Concert Pharmaceuticals in a report on Friday, January 12th. Finally, TheStreet upgraded Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Monday, January 8th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $25.67.

In other Concert Pharmaceuticals news, Director Richard Aldrich sold 11,946 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $20.89, for a total value of $249,551.94. Following the sale, the director now owns 286,975 shares in the company, valued at approximately $5,994,907.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 105,000 shares of company stock worth $2,090,706 in the last 90 days. Company insiders own 10.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply